Pharma
Global Irritable Bowel Syndrome Treatment Market Opportunities and Forecast 2020-2027
  • DLR2997
  • 17 February, 2022
  • Pharma & Healthcare
  • Pages: 120
  • Global
Global Irritable Bowel Syndrome Treatment Market, By Type (IBS with Diarrhea (IBS-D), IBS with Constipation (IBS-C), Mixed-presentation IBS (IBS-M)) By Product (Rifaximin, Eluxadoline, Lubiprostone, Linaclotide, Others) By End User (Hospitals Pharmacies, Drug Stores & Retail Pharmacies, Online Pharmacies), and opportunities and forecast 2020-2027

Irritable Bowel Syndrome Treatment Market Overview

Irritable bowel syndrome (IBS) affects the large intestine and is a common gastrointestinal illness. Abdominal pain, bloating, gas, cramps, and constipation or diarrhoea are some of the signs and symptoms. Irritable bowel syndrome is divided into three categories: diarrhoea (IBS-D), constipation (IBS-C), and mixed IBS.
 
Major reasons driving the growth of the irritable bowel syndrome treatment market include an increase in the elderly population, an increase in the prevalence of gastrointestinal diseases and disorders such as bowel habit change and abdominal pain, a rise in stress levels, and an unhealthy diet. Other factors that contribute to the market's growth include an increase in awareness initiatives regarding the treatment and management of irritable bowel syndrome, as well as a surge in interest in IBS treatments that improve therapeutic outcomes. Furthermore, the developing economies' untapped potential presents profitable chances for market expansion during the projection period.

However, the lack of a particular medication that addresses all of the symptoms of IBS and strong pricing competition among leading providers are projected to limit market expansion.

Report Metric Details
Market size available for years 2019–2027
Base year considered 2019
Forecast period 2020–2027
Forecast unit Value (USD Million)
Segments covered Type, Product, End User, and Region.
Regions covered North America (the U.S. and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South East Asia, Rest of Asia Pacific), Latin America and the Middle East and Africa (Brazil, Saudi Arabia, UAE, Rest of LAMEA)
Companies covered Abbott Laboratories, Allergan plc, Ardelyx Inc., Astellas Pharma Inc., AstraZeneca plc, GlaxoSmithKline Plc, Johnson & Johnson (McNeil Consumer Healthcare), Novartis AG, Sebela Pharmaceuticals Inc., and Takeda Pharmaceutical Company Ltd.


Covid-19 Impact on Irritable Bowel Syndrome Treatment Market
 
In addition, the current Irritable Bowel Syndrome Treatment Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the Irritable Bowel Syndrome Treatment Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long term as well as short term effect which includes supply shortages, panic buying, and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.

The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2020 and its projection up to 2027 is provided in detail in this report.

Irritable Bowel Syndrome Treatment Market Segment Overview



According to Type, the IBS with diarrhoea (IBS-D) segment dominated the irritable bowel syndrome treatment market. Furthermore, this segment is expected to grow at the fastest rate during the forecast period, owing to an increase in the prevalence of gastrointestinal diseases like constipation and diarrhoea as a result of changing lifestyles, an increase in the geriatric population, a surge in the uptake of drugs like linaclotide and lubiprostone, and an increase in patient awareness about the treatment of irritable bowel syndrome.
 
Irritable Bowel Syndrome Treatment Market, By Type
·       IBS with Diarrhea (IBS-D)
·       IBS with Constipation (IBS-C)
·       Mixed-presentation IBS (IBS-M)

Irritable Bowel Syndrome Treatment Market, By Product
·       Rifaximin
·       Eluxadoline
·       Lubiprostone
·       Linaclotide
·       Others

Irritable Bowel Syndrome Treatment Market, By End User
·       Hospitals Pharmacies
·       Drug Stores & Retail Pharmacies
·       Online Pharmacies

Irritable Bowel Syndrome Treatment Regional Overview

In terms of geography, the global Irritable Bowel Syndrome Treatment market is classified into North America, South America, Europe, Asia Pacific, and Middle East & Africa. Asia-Pacific is one of the most prominent regions in the global Irritable Bowel Syndrome Treatment market. Asia-Pacific offers lucrative potential for key participants in the irritable bowel syndrome treatment market, as well as increased knowledge of the condition's treatment and adoption of irritable bowel syndrome treatment products. Furthermore, developments in healthcare infrastructure, an increase in the number of hospitals with superior medical facilities, a growing R&D sector, increased healthcare reforms, and technical advancements in the field of healthcare all contribute to market growth.
 
Other factors driving the growth of the Asia-Pacific irritable bowel syndrome treatment market include leading manufacturers' increased focus on expanding their geographic presence in emerging Asia-Pacific countries to capture high growth opportunities in the market, a large population base, and high disposable incomes.

Irritable Bowel Syndrome Treatment Market, By Geography

·       North America (US & Canada)
·       Europe (UK, Germany, France, Italy, Spain, Russia & Rest of Europe)
·       Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
·       LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
  
Irritable Bowel Syndrome Treatment Market, Key Players

·       Abbott Laboratories
·       Allergan plc
·       Ardelyx Inc.
·       Astellas Pharma Inc.
·       AstraZeneca plc
·       GlaxoSmithKline Plc
·       Johnson & Johnson (McNeil Consumer Healthcare)
·       Novartis AG
·       Sebela Pharmaceuticals Inc.
·       Takeda Pharmaceutical Company Ltd.

Frequently Asked Questions (FAQ) :

Q1. What are the driving factors for the global Irritable Bowel Syndrome Treatment market?

A. Major reasons driving the growth of the irritable bowel syndrome treatment market include an increase in the elderly population, an increase in the prevalence of gastrointestinal diseases and disorders such as bowel habit change and abdominal pain, a rise in stress levels, and an unhealthy diet

Q2. What are the restraining factors for the global Irritable Bowel Syndrome Treatment market?

A. The lack of a particular medication that addresses all of the symptoms of IBS and strong pricing competition among leading providers are projected to limit market expansion

Q3. Which segment is projected to hold the largest share in the global Irritable Bowel Syndrome Treatment market?

A. IBS with diarrhoea (IBS-D) segment is projected to hold the largest share in the global Irritable Bowel Syndrome Treatment market

Q4. Which region holds the largest share in the global Irritable Bowel Syndrome Treatment market?

A. North America holds the largest share in the global Irritable Bowel Syndrome Treatment market.

Q5. Which are the prominent players in the global Irritable Bowel Syndrome Treatment market?

A. Abbott Laboratories, Allergan plc, Ardelyx Inc., Astellas Pharma Inc., AstraZeneca plc, GlaxoSmithKline Plc, Johnson & Johnson (McNeil Consumer Healthcare), Novartis AG, Sebela Pharmaceuticals Inc., and Takeda Pharmaceutical Company Ltd. are some key players in the global Irritable Bowel Syndrome Treatment market
Irritable Bowel Syndrome Treatment Market Study Global Market Analysis, Insights and Forecast, 2020-2027

    1. Introduction

    • 1.1. Research Scope
    • 1.2. Market Segmentation
    • 1.3. Research Methodology
    • 1.4. Definitions and Assumptions

    2. Executive Summary

      3. Market Dynamics

      • 3.1. Market Drivers
      • 3.2. Market Restraints
      • 3.3. Market Opportunities

      4. Key Insights

      • 4.1. Key Emerging Trends – For Major Countries
      • 4.2. Latest Technological Advancement
      • 4.3. Regulatory Landscape
      • 4.4. Industry SWOT Analysis
      • 4.5. Porters Five Forces Analysis

      5. Global Irritable Bowel Syndrome Treatment Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 5.1. Key Findings / Summary
      • 5.2. Market Analysis, Insights and Forecast – By Type
        • 5.2.1. IBS with Diarrhea (IBS-D)
        • 5.2.2. IBS with Constipation (IBS-C)
        • 5.2.3. Mixed-presentation IBS (IBS-M)
      • 5.3. Market Analysis, Insights and Forecast – By Product
        • 5.3.1. Rifaximin
        • 5.3.2. Eluxadoline
        • 5.3.3. Lubiprostone
        • 5.3.4. Linaclotide
        • 5.3.5. Others
      • 5.4. Market Analysis, Insights and Forecast – By End User
        • 5.4.1. Hospitals Pharmacies
        • 5.4.2. Drug Stores & Retail Pharmacies
        • 5.4.3. Online Pharmacies
      • 5.5. Market Analysis, Insights and Forecast – By Region
        • 5.5.1. North America
        • 5.5.2. Europe
        • 5.5.3. Asia Pacific
        • 5.5.4. Latin America, Middle East and Africa

      6. North America Irritable Bowel Syndrome Treatment Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 6.1. Key Findings / Summary
      • 6.2. Market Analysis, Insights and Forecast – By Type
        • 6.2.1. IBS with Diarrhea (IBS-D)
        • 6.2.2. IBS with Constipation (IBS-C)
        • 6.2.3. Mixed-presentation IBS (IBS-M)
      • 6.3. Market Analysis, Insights and Forecast – By Product
        • 6.3.1. Rifaximin
        • 6.3.2. Eluxadoline
        • 6.3.3. Lubiprostone
        • 6.3.4. Linaclotide
        • 6.3.5. Others
      • 6.4. Market Analysis, Insights and Forecast – By End User
        • 6.4.1. Hospitals Pharmacies
        • 6.4.2. Drug Stores & Retail Pharmacies
        • 6.4.3. Online Pharmacies
      • 6.5. Market Analysis, Insights and Forecast – By Country
        • 6.5.1. U.S.
        • 6.5.2. Canada

      7. Europe Irritable Bowel Syndrome Treatment Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 7.1. Key Findings / Summary
      • 7.2. Market Analysis, Insights and Forecast – By Type
        • 7.2.1. IBS with Diarrhea (IBS-D)
        • 7.2.2. IBS with Constipation (IBS-C)
        • 7.2.3. Mixed-presentation IBS (IBS-M)
      • 7.3. Market Analysis, Insights and Forecast – By Product
        • 7.3.1. Rifaximin
        • 7.3.2. Eluxadoline
        • 7.3.3. Lubiprostone
        • 7.3.4. Linaclotide
        • 7.3.5. Others
      • 7.4. Market Analysis, Insights and Forecast – By End User
        • 7.4.1. Hospitals Pharmacies
        • 7.4.2. Drug Stores & Retail Pharmacies
        • 7.4.3. Online Pharmacies
      • 7.5. Market Analysis, Insights and Forecast – By Country
        • 7.5.1. UK
        • 7.5.2. Germany
        • 7.5.3. France
        • 7.5.4. Italy
        • 7.5.5. Spain
        • 7.5.6. Russia
        • 7.5.7. Rest of Europe

      8. Asia Pacific Irritable Bowel Syndrome Treatment Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 8.1. Key Findings / Summary
      • 8.2. Market Analysis, Insights and Forecast – By Type
        • 8.2.1. IBS with Diarrhea (IBS-D)
        • 8.2.2. IBS with Constipation (IBS-C)
        • 8.2.3. Mixed-presentation IBS (IBS-M)
      • 8.3. Market Analysis, Insights and Forecast – By Product
        • 8.3.1. Rifaximin
        • 8.3.2. Eluxadoline
        • 8.3.3. Lubiprostone
        • 8.3.4. Linaclotide
        • 8.3.5. Others
      • 8.4. Market Analysis, Insights and Forecast – By End User
        • 8.4.1. Hospitals Pharmacies
        • 8.4.2. Drug Stores & Retail Pharmacies
        • 8.4.3. Online Pharmacies
      • 8.5. Market Analysis, Insights and Forecast – By Country
        • 8.5.1. China
        • 8.5.2. India
        • 8.5.3. Japan
        • 8.5.4. Australia
        • 8.5.5. South East Asia
        • 8.5.6. Rest of Asia Pacific

      9. Latin America, Middle East and Africa Irritable Bowel Syndrome Treatment Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 9.1. Key Findings / Summary
      • 9.2. Market Analysis, Insights and Forecast – By Type
        • 9.2.1. IBS with Diarrhea (IBS-D)
        • 9.2.2. IBS with Constipation (IBS-C)
        • 9.2.3. Mixed-presentation IBS (IBS-M)
      • 9.3. Market Analysis, Insights and Forecast – By Product
        • 9.3.1. Rifaximin
        • 9.3.2. Eluxadoline
        • 9.3.3. Lubiprostone
        • 9.3.4. Linaclotide
        • 9.3.5. Others
      • 9.4. Market Analysis, Insights and Forecast – By End User
        • 9.4.1. Hospitals Pharmacies
        • 9.4.2. Drug Stores & Retail Pharmacies
        • 9.4.3. Online Pharmacies
      • 9.5. Market Analysis, Insights and Forecast – By Country
        • 9.5.1. Brazil
        • 9.5.2. Saudi Arabia
        • 9.5.3. UAE
        • 9.5.4. Rest of LAMEA

      10. Competitive Analysis

      • 10.1. Company Market Share Analysis, 2018
      • 10.2. Key Industry Developments
      • 10.3. Company Profile
      • 10.4. Abbott Laboratories
        • 10.4.1. Business Overview
        • 10.4.2. Segment 1 & Service Offering
        • 10.4.3. Overall Revenue
        • 10.4.4. Geographic Presence
        • 10.4.5. Recent Development
      *Similar details will be provided for the following companies
      • 10.5. Allergan plc
      • 10.6. Ardelyx Inc.
      • 10.7. Astellas Pharma Inc.
      • 10.8. AstraZeneca plc
      • 10.9. GlaxoSmithKline Plc
      • 10.10. Johnson & Johnson (McNeil Consumer Healthcare)
      • 10.11. Novartis AG
      • 10.12. Sebela Pharmaceuticals Inc.

      Report You Might be Interested

      Choose License Type

      • USD
      • GBP
      • EURO
      • INR
      Credit card Logo

      Happy To Assist You

      Have a Question? email us at

      info@datalibraryresearch.com

      Or Call Us On

      US +1 360 851 1343

      IND +91 880 579 4934